Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas | MicrobiomeTrials← Back to trialsNCT04750928
Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2021-11-29Est. Completion: 2028-12-31
Enrollment target: 55 participants Locations- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Other microbiome trials you might be interested in
Neurofibromatosis Type 1Neurofibroma
This study will explore the growth of dermal neurofibromas (skin tumors) in patients with neurofibromatosis type 1 (NF1)…
Bethesda, United States
Neurofibromatosis Type 1Malignant Peripheral Nerve Sheath TumorPlexiform NeurofibromaOptic GliomaNeurofibroma
Background:
Neurofibromatosis Type 1 (NF1) is a genetic disorder in which patients are at increased risk of developing …
Bethesda, United States